S&P 500
(0.16%) 5 222.68 points

Dow Jones
(0.32%) 39 513 points

Nasdaq
(-0.03%) 16 341 points

Oil
(-1.34%) $78.20

Gas
(-2.13%) $2.25

Gold
(1.14%) $2 366.90

Silver
(0.11%) $28.40

Platinum
(1.48%) $1 005.50

USD/EUR
(0.11%) $0.928

USD/NOK
(-0.30%) $10.83

USD/GBP
(-0.01%) $0.798

USD/RUB
(-0.42%) $92.15

Realtime updates for Merus NV [MRUS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

BUY

100.00%
return 12.35%

SELL

40.00%
return -4.33%

Last Updated10 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

-1.33% $ 44.52

BUY 125186 min ago

@ $42.61

Issued: 14 Feb 2024 @ 14:47

Return: 4.48%

Previous signal: Feb 13 - 15:34

Previous signal: Sell

Return: 1.44 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1...

Stats
Today's Volume	1.07M
Average Volume	620 616
Market Cap	2.58B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.890 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.84
ATR14	$0.0840 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-07	Haddock Jason	Buy	17 688	Share Option (right to buy)
2024-05-07	Pucci Paolo	Buy	8 844	Share Option (right to buy)
2024-05-07	Shuman Harry	Buy	27 550	Share Option (right to buy)
2024-05-07	Lundberg Sven Ante	Buy	360 000	Share Option (right to buy)
2024-05-07	Haddock Jason	Buy	0

INSIDER POWER
85.40
Last 98 transactions
Buy: 3 333 163 \| Sell: 3 625 693

Volume Correlation

Long: -0.10 (neutral)

Short: 0.16 (neutral)

Signal:(47.851) Neutral

Merus NV Correlation

10 Most Positive Correlations
HOWL	0.948
YMAB	0.946
CGEM	0.943
SLN	0.941
NVCN	0.937
REYN	0.935
KYMR	0.934
BRIVU	0.931
PPH	0.929
VERA	0.929

10 Most Negative Correlations
WINT	-0.939
REVB	-0.937
VALN	-0.937
BIOL	-0.933
SRNGW	-0.933
VRM	-0.931
LHDX	-0.931
SGML	-0.93
TENX	-0.928
IMV	-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Merus NV Correlation - Currency/Commodity

0.22
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.30
( neutral )

-0.32
( neutral )

-0.35
( neutral )

Merus NV Financials

Annual	2023
Revenue:	$43.95M
Gross Profit:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2023
Revenue:	$43.95M
Gross Profit:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2022
Revenue:	$41.59M
Gross Profit:	$29.60M (71.19 %)
EPS:	$-2.92

FY	2021
Revenue:	$49.11M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.730

Financial Reports:

No articles found.

Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.